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Abstract 
Background 
Mefloquine is recommended in international health guidelines for preventing malaria in travellers. 
Reports of psychosis and suicide are often alluded to but are not clearly established.  
Methods 
We carried out a systematic review to identify and critically appraise any death or parasuicide 
associated with mefloquine prophylaxis. We developed a comprehensive search that included 
publications up to 11 July 2017. We included case studies but excluded newspaper reports. Two 
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authors independently appraised each death or parasuicide against a standardised causality 
assessment tool. The protocol was registered on PROSPERO (CRD42016041988). 
Results 
We identified 527 articles that required full-text retrieval; of these 17 were unique publications that 
reported deaths or parasuicide. Eight unique publications had sufficient detail to be included in 
causality assessment.  We identified 2 deaths with a probable association that appeared to be 
idiosyncratic drug reactions; we categorised the remaining 8 deaths as “unlikely” to be related to 
mefloquine, or “unclassifiable”.  There was one parasuicide with a possible causal association. 
There were 9 additional publications that searched spontaneous drug reporting databases; none 
provided sufficient detail to perform a causality assessment. 
Conclusions 
Overall, the number of deaths that we could reliably attribute to the prophylactic use of mefloquine 
is very low.  
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1 Introduction 
Mefloquine has been widely available for use in Europe and the USA since the late 1980s. Many 
international health guidelines recommend mefloquine as standard prophylaxis in travellers to 
malaria endemic areas [1,2,3,4].  
Mefloquine often causes mild headaches and dizziness [5], but also vivid dreams and mood changes. 
These effects have given rise to beliefs that the drug can result in suicide and psychosis. The 
occurrence, frequency and severity of these events and their attribution to mefloquine have been 
the subject of heated debate. In 2013, the US Food and Drug Administration (FDA) issued a “boxed 
warning” about mefloquine and risk of neurological or psychiatric events, with special warnings to be 
given to users. However, there remains a lack of clarity over the evidence base for this, and concerns 
these developments limit the use of an important drug in preventing malaria in travellers [6]. 
Nevertheless, recently the UK Defence Committee concluded that mefloquine should only be used as 
a “drug of last resort” [7]. 
The side-effects of mefloquine are well documented: abnormal dreams, insomnia, anxiety and 
depressed mood, as well as nausea and dizziness. The recent Cochrane Review documents this and 
estimates absolute effects [8]. Whilst this is not contested, what is uncertain is the evidence related 
to the drug causing death or suicide.  
The previous edition of the Cochrane Review on mefloquine included a table in an annex that the 
authors’ referred to in the review’s discussion relating to mefloquine and death. The Cochrane 
Infectious Diseases Group editorial team audited this table, which listed case reports of deaths and 
deaths due to suicide that had been attributed to mefloquine [9]. Some of the sources listed were 
when the drug was used in treatment, and others counted deaths in reviews that were not verifiable, 
and there were other errors and double counting across reviews. The Co-ordinating Editor of the 
Group (who is the last author of this paper) made the decision to withdraw the review because this 
information appeared misleading. The Cochrane Review has now been replaced with a new 2017 
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edition, prepared by a new author team using up-to-date methods drawing on cohort studies as well 
as trials [8]. 
In parallel with the preparation of the new edition of the Cochrane Review, we have conducted a 
systematic review of all reports of deaths, which we report here. This review draws on all possible 
reports, and applies a standard causality framework as this appears to be the most useful approach 
to critically appraise and assess the quality of these reports. In light of suggestions that mood change 
and suicide with the drug were connected, we also sought and appraised reports of parasuicide. The 
author team wrote and agreed the review protocol in advance [10], and the objectives were as 
follows. 
• To identify all possible reported deaths or episodes of parasuicide associated with 
mefloquine used at a prophylactic dose in publicly available literature. 
• To critically appraise each case using a formal causality assessment. 
2 Materials and methods 
2.1 Inclusion criteria 
2.1.1 Types of studies 
We included all forms of prospective and retrospective studies of individual case reports or reviews 
of case reports that reported deaths or parasuicide. Newspaper articles were excluded. 
2.1.2 Types of participants 
Adults, including pregnant women, and children of all ages. 
2.1.3. Types of interventions 
Mefloquine at a prophylactic dose. This included the current recommendation (250 mg weekly), and 
previously used doses, such as 360 mg weekly, 180 mg weekly and 500 mg fortnightly. 
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2.1.4 Types of outcome measures 
• Death. 
• Parasuicide (the act of committing suicide without the resulting death.  Objectively and 
subjectively, the actions taken were intended to result in death). 
2.2 Search strategy 
We attempted to identify all relevant studies regardless of language or publication status (published, 
unpublished, in press and ongoing). 
We searched the following databases using the search terms described in Figure 1: the Cochrane 
Infectious Diseases Group Specialized Trials Register; the Cochrane Central Register of Controlled 
Trials (CENTRAL), published in the Cochrane Library; PubMed (MEDLINE); Toxicology Literature 
Online (TOXLINE);  Embase (OVID); the Science Citation Index Expanded™, accessed via Web of 
Science;  and LILACS. We also searched the following ongoing trials registers: the metaRegister of 
Controlled trials (www.controlled-trials.com); the U.S. National Institutes of Health Register 
Figure 1. PubMed search strategy* 
1.  (("Mefloquine"[Mesh]) OR lariam OR mefloquin* Field: Title/Abstract 
2. malaria* OR antimalaria* OR plasmodium OR prophyla* OR chemoprophyla* OR prevent* 
OR chemoprevent* Field: Title/Abstract 
3. exp "Mental Disorders"[Mesh] OR (adverse OR neurotox* OR psychiatr* OR neuropsych* 
OR psycho* OR suicid* OR death* OR mortality OR fatal* OR neurol* OR ototox* OR depress* OR 
anxiety OR toxic* OR safety OR tolerab* OR reaction* OR “side effect*” OR severe OR disorder* 
OR dizziness OR headache* OR mental) Field: Title/Abstract 
4.   #1 and #2 and #3 
5. ( "Mefloquine/adverse effects"[Mesh] OR  "Mefloquine/contraindications"[Mesh] OR  
"Mefloquine/poisoning"[Mesh] OR  "Mefloquine/toxicity"[Mesh] ) 
6. 4 or 5 
7. ((military or soldier* OR army or force or defence or deploy* OR personnel )) Field: 
Title/Abstract OR "Military Personnel"[Mesh] OR "Military Facilities"[Mesh] 
8. 1 AND 7 
9. 6 OR 8  
* Search strategies for the other listed databases are available on request. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6 
(www.clinicaltrials.gov); and the World Health Organization (WHO) International Clinical Trials 
Registry platform (ICTRP) (www.who.int/trialsearch), to identify ongoing studies.  
We searched the following websites:  Medicines and Healthcare Products Regulatory Agency (UK; 
www.mhra.gov.uk); European Medicines Agency (www.emea.eu);  Database of Adverse Effects 
Notification (Australia, www.tga.gov.au/database-adverse-event-notifications-daen); FDA Medwatch 
(USA, www.FDA.gov/safety/Medwatch); UK Parliament website (www.parliament.uk/).  
We checked the reference lists of each included paper for other potentially relevant studies. At full-
text screening stage, we compiled a database of any articles that mentioned death or parasuicide 
associated with mefloquine prophylaxis. We then checked the reference list of each of these papers 
and retrieved the original full-text case reports (where available). 
For each published review of deaths due to mefloquine, including the withdrawn Cochrane Review 
[9], we compared the primary citation for each death and compiled a list of the unique death 
reports. We contacted authors, where necessary, to obtain full descriptions of any deaths or 
episodes of parasuicide. 
2.3 Methods 
2.3.1 Selection of studies   
Two authors independently screened the results of the literature search for potentially relevant 
trials, studies or case reports, and looked for multiple publications from the same data set. Full text 
copies were retrieved of all trials deemed potentially relevant. 
Two authors then independently assessed all identified trials, studies or case reports for inclusion in 
the review using the pre-stated inclusion criteria. Any disagreement was resolved through discussion 
and where necessary a third author was consulted. We have reported all reasons for excluding any 
identified studies. 
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2.3.2 Data extraction and management   
Two authors independently extracted data using a standardized and pre-piloted data collection form. 
When available, we extracted the following information. 
• Study: design, year, country of origin and country of malaria exposure. 
• Intervention: drug dose during prophylaxis, use of a loading dose, number of doses taken, 
frequency of drug administration and use of any co-interventions. 
• Participant: age, sex, body mass index (BMI), occupation, past medical history, proceeding 
symptoms, use of other medications (prescribed and recreational). 
• Outcome: circumstances of death or parasuicide, timing in relation to treatment, duration 
and frequency of monitoring, method of detection. 
2.3.3 Assessment of causality 
We extracted data on all reports of death. Two authors independently critically appraised each 
report using ‘The WHO-UMC system for standardised case causality assessment’ tool’ (Figure 2) [11]. 
This classifies the event into “certain”, “probable”, “possible” or “unlikely” depending on the strength 
of the association with the study drug. Where the information presented was poor or conclusions 
could not be drawn, we categorised the event as "unclassifiable". We have included all reports in the 
final review, regardless of classification. Any disagreement was resolved through discussion, and 
where necessary a third author was consulted. 
2.3.4 Dealing with missing data   
If data from the papers was insufficient, unclear or missing, we contacted the authors for additional 
information. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8 
Term Description
 
Comment
 
Certain “A clinical event, including laboratory test 
abnormality, occurring in a plausible time 
relationship to drug administration, and 
which cannot be explained by concurrent 
disease or other drugs or chemicals. The 
response to withdrawal of the drug (de-
challenge) should be clinically plausible. 
The event must be definitive 
pharmacologically or 
phenomenologically, using a satisfactory 
re-challenge procedure if necessary.” 
It is recognized that this stringent definition will lead 
to very few reports meeting the criteria, but this is 
useful because of the special value of such reports. It 
is considered that time relationships between drug 
administration and the onset and course of the 
adverse event are important in causality analysis. So 
also is the consideration of confounding features, but 
due weight must be placed on the known 
pharmacological and other characteristics of the drug 
product being considered. Sometimes the clinical 
phenomena described will also be sufficiently specific 
to allow a confident causality assessment. 
Probable A clinical event, including laboratory test 
abnormality, with a reasonable time 
sequence to administration of the drug, 
unlikely to be attributed to concurrent 
disease or other drugs or chemicals, and 
which follows a clinically reasonable 
response on withdrawal (de-challenge). 
Re-challenge information is not required 
to fulfil this definition. 
This definition has less stringent wording than for 
"certain" and does not necessitate prior knowledge of 
drug characteristics or clinical adverse reaction 
phenomena. As stated, no re-challenge information is 
needed, but confounding drug administration and 
underlying disease must be absent. 
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Possible A clinical event, including laboratory test 
abnormality, with a reasonable time 
sequence to administration of the drug, 
but which could also be explained by 
concurrent disease or other drugs or 
chemicals. Information on drug 
withdrawal may be lacking or unclear. 
This is the definition to be used when drug causality is 
one of other possible causes for the described clinical 
event. 
Unlikely A clinical event, including laboratory test 
abnormality, with a temporal 
relationship to drug administration which 
makes a causal relationship improbable, 
and in which other drugs, chemicals or 
underlying disease provide plausible 
explanations. 
This definition is intended to be used when the 
exclusion of drug causality of a clinical event seems 
most plausible. 
Un-
assessable/ 
unclassifiable 
A report suggesting an adverse reaction 
which cannot be judged because 
information is insufficient or 
contradictory, and which cannot be 
supplemented or verified. 
This definition is used when insufficient information is 
available to perform a causality assessment. 
Figure 2. Framework for causality assessment [11]. These descriptions are based on the WHO-UMC 
causality assessments, with appropriate modifications for this review. 
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3 Results 
3.1 Description of studies 
Our electronic search was performed on 11 July 2017 and identified 2523 citations. Screening the 
reference list of all papers referring to deaths associated with mefloquine prophylaxis identified an 
additional 2 case reports. After removal of duplicates, 2521 articles were retrieved. 
Of these, we excluded 1993 at the title and abstract screening stages and retrieved 528 full-text 
reports. We did not identify any ongoing studies or studies awaiting classification. 
Of these 528, 457 did not meet our inclusion criteria and were excluded for the reasons detailed in 
Figure 3.  
A total of 71 studies mentioned mefloquine being potentially linked to death or parasuicide. Of 
these, 17 were unique publications which referred to death or parasuicide in users of mefloquine 
prophylaxis. Fifty-four articles were excluded after full-text assessment. 
Eight publications were individual reports of death or parasuicide and are included with a full 
causality assessment (Table 1). Three of these were case reports in peer-reviewed journals and one 
additional case report was from a drug safety newsletter. Two were retrospective cohort studies and 
one was a randomised controlled trial in pregnant women. The eighth publication was a review 
article about suicide in US soldiers. 
Nine publications included multiple reports of death reported in reviews that had been derived from 
spontaneous drug reporting databases. All of these reports had insufficient information to apply 
causality assessment (Table 2). These publications searched a total of five databases across a variety 
of dates including the National French Pharmacovigilance database, the Roche Drug Safety 
Department, the Spanish Pharmacovigilance System, the UK Medicines and Healthcare Products 
Regulatory Agency Yellow Card Scheme and the US FDA. 
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The 54 publications excluded after full-text assessment are detailed in Table 3. Thirty articles referred 
to publications included in our main analysis; 7 made reference to mefloquine being linked to 
suicide, but did not provide a reference; 6 referred to case reports of mefloquine being linked to 
suicide, however, the reference(s) provided did not include any reports of death or parasuicide; 3 
were case reports in which mefloquine was used at treatment dose; 3 did not provide sufficient 
detail to meet our inclusion criteria (for example, dose not specified); 3 referred to a death in a user 
of mefloquine prophylaxis but the reference provided was a newspaper article; and 2 were excluded 
for other reasons.  
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Figure 3. Study flow diagram 
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3.2 Causality assessment 
 
For the 8 publications that we applied the formal causality assessment, the results are shown in 
Table 1. We identified 2 deaths with a probable causal association with mefloquine prophylaxis, and 
1 parasuicide with a possible causal association. The probable deaths were caused by what appeared 
to be idiosyncratic drug reactions (pulmonary fibrosis; exfoliative illness with neutropenia). We 
classified 8 other individual reports of death as “unclassifiable” or “unlikely” using the causality 
framework.  
4. Discussion 
 
We identified two deaths with a probable causal association with mefloquine prophylaxis, and one 
parasuicide with a possible causal association. The application of rigorous procedures, ensuring 
deaths were not double counted, and applying a causality assessment results in a much smaller 
number of deaths than previously cited in the discussion section of an older edition of the Cochrane 
Review on the topic which reported that 22 deaths, including 5 suicides, were caused by mefloquine 
[8,30].  
Whether the reported deaths were correctly attributed to the use of mefloquine prophylaxis is an 
important clinical question, as the risk of death in a previously healthy population is unacceptable to 
both prescribers and users of malaria prophylaxis. As this old data set was contained as an annex 
with no methods, we have repeated the analysis with a new search strategy and formal causality 
assessment. Our assessment indicates the previous estimate was incorrect.  
We were rigorous in our application of the criteria and in resolving discrepancies so that the 
approach was standardised across all cases identified. However, there are some, it has been pointed 
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out to us, such as Table 1 FDA 2008 [15] might be better classified as “unlikely” or “unclassifiable”. 
Whilst we would agree these are difficult decisions, our approach has been to maintain the 
judgements made by the team, rather than adjusting in the light of subsequent comments on 
selected cases. Determination of causality is very complicated where people are in highly stressful 
situations which in themselves can cause sleeplessness and stress; and psychological and psychiatric 
disturbances after active military duty can be common: Marvasti 2013 in Table 1 illustrates this [16]. 
Designing a systematic review to assess the risk of a rare outcome of an intervention, such as death, 
poses specific methodological challenges. Randomised controlled trials and cohort studies are 
usually not powered to detect uncommon outcomes.  Therefore, systematic evaluation of these 
outcomes requires the inclusion of other study designs such as case reports, case series and 
spontaneous reporting systems [31]. These study designs have their own limitations [32]. 
One problem with these methods of pharmacovigilance is that death is too rare an outcome to allow 
a robust statistical analysis to evaluate the likelihood that a particular treatment is the cause of a 
particular adverse event [33]. Therefore, each individual case report requires a formal causality 
assessment. Many different methods have been proposed; however, so far no approach has shown 
consistent and reproducible results and therefore there is currently no gold standard methodology 
[33]. The WHO-UMC system used in this paper was designed as a combined assessment, considering 
the clinical-pharmacological aspects of the case history and the quality of the recorded observations 
[11]. Despite its limitations, this remains the most widely used method in causality assessment, 
largely due to its ease of use and easy-to-follow classification system [33]. 
 
However, regardless of the methodology used to determine causality, our main limiting factor was 
the poor reporting of this topic within the academic literature. Despite extensive searching, we only 
found a few reports that provided us with sufficient detail to perform a formal causality assessment. 
Even where case reports did provide sufficient information, quality concerns remained; a good 
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example comes from a widely-reported case [34,35] that contained significant discrepancies 
regarding the dose of mefloquine across different publications of the same report. We received 
confirmation through personal communication with the author that mefloquine was in fact taken at 
a treatment dose for presumed malaria illness and thus excluded from our analysis (Jousset, personal 
communication). 
Case reports or case series are absolutely confounded by publication bias. In other words, if the 
event occurs then such cases are likely to be written up and reported in a journal, whereas if there is 
no event they will not be reported. However, what was striking here was how few reports we found, 
despite exhaustive searching.  
Publications that included analyses of spontaneous drug reporting databases provided additional 
interesting information. These databases were developed after the thalidomide incident and are 
used in the identification of signals of new, rare and serious adverse drug reactions [36]. They 
provide a large volume of reports, but often contain little or no additional information, and usually 
have insufficient detail to critically appraise causality. These reports have appeared in previous 
reviews of severe adverse effects of mefloquine, but when we examined the information reported 
none had sufficient detail to apply the causality framework.  We have intentionally not provided a 
summary estimate of the number of deaths associated with mefloquine use in these analyses (Table 
2). Collections of adverse reactions to spontaneous reporting systems occur from all available 
sources including the lay and scientific press, national and international regulatory authority 
databases, consumers and medical and paramedical practitioners. Therefore, it is likely that events 
are reported more than once, by different doctors or by both doctor and patient, as well as to more 
than one spontaneous reporting system. There are also discrepancies between different searches of 
the same database. Only one of these analyses performed a causality assessment of the reported 
cases [21], and there was insufficient detail for us to provide a robust estimate ourselves. 
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Our findings differ from previous analyses of the same topic [9, 30], which have included several 
references to grey literature, including newspaper articles; in our opinion this should be avoided in 
the scientific analysis of controversial topics such as this one.  
Overall, the number of deaths that we could reliably attribute to the prophylactic use of mefloquine 
was much lower than has previously been reported. However, due to poor reporting of this topic 
within the literature, we cannot provide a single summary estimate.  
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Table 1. Case reports of deaths in users of mefloquine prophylaxis: causality assessment 
Primary 
reference 
Type of 
study 
Clinical summary Classification Justification 
Anon 2001 
[12,13] 
Case report 
in a peer-
reviewed 
journal 
A previously healthy 22 year old began mefloquine 
prophylaxis 1 week prior to travel. 8 days later he 
developed fever, chills, headache and cough. He was 
diagnosed with malaria and bronchopneumonia and was 
treated orally with halofantrine, dirithromycin and 
acetylcysteine. Two days later, he stepped from a car, 
complained of a ‘head rush’, then collapsed and died. 
Autopsy revealed a previously undiagnosed atypical 
asymmetric hypertrophic cardiomyopathy. 
Unlikely Halofantrine has been 
commonly associated with 
cardiac arrhythmias as it causes 
prolongation of the QT interval 
(it was discontinued for this 
reason) and is the more likely 
cause of a potential dysrhythmia 
in this patient with previously 
undiagnosed cardiomyopathy. 
Eick-Cost 2017 
[14] 
Retrospective 
cohort study 
Two soldiers who received a prescription for mefloquine 
(from a cohort of 36,538) committed suicide. In the same 
cohort study, 15 soldiers who received a prescription for 
doxycycline (cohort size 318,421), and one who received a 
prescription for atovaquone-proguanil also committed 
suicide (cohort size 12,881). 
Unclassifiable This was a retrospective analysis 
of prescription data and the 
individuals were never 
contacted. Therefore, it is not 
possible to confirm whether the 
mefloquine prescriptions was 
ever taken and, if so, the 
occurrence of this event in 
relation to treatment use. There 
is also no past medical history 
and no information about any 
co-medications for either 
participant. 
FDA 2008 [15] Case report 
in a drug 
safety 
newsletter 
A 4 year old female patient died from pulmonary fibrosis 
and interstitial pneumonitis. She was started on 
mefloquine 75 mg per week prior to travelling. The patient 
had previously taken mefloquine (unknown date). During 
Probable The event occurred following a 
reasonable time sequence to 
when the drug was taken. There 
was no past medical history and 
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the trip, she experienced rash and fever at night, but was 
afebrile during the day. She was given an antibiotic for a 
suspected infection, although subsequent tests revealed no 
evidence of this.  
On her return, she was hospitalized with suspected 
inflammatory disease, but no specific diagnosis was given. 
She was continued on the mefloquine and received 
corticosteroids which led to some improvement. After 45 
days, her general state of health worsened. She started to 
cough and developed interstitial pneumonitis. Mefloquine 
was discontinued. A chest radiograph showed bilateral 
infiltration confluent in the lung. She was intubated and 
ventilated due to her rapidly progressive lung failure. A 
pulmonary biopsy showed autoimmune interstitial 
alveolitis. She was treated with high dose corticosteroids, 
plasmapheresis and immunoglobulins. After five weeks of 
extracorporeal membrane oxygenation (ECMO) treatment, 
the patient died suddenly.  
no alternative drug regime used 
to provide an alternative 
explanation. Symptoms 
continued to progress despite 
the withdrawal of mefloquine, 
making de-challenge difficult to 
analyse. This is presented as a 
series of 12 cases where 
mefloquine was associated with 
pneumonitis. 
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Marvasti 2013 
[16] 
Review 
article about 
suicides in US 
soldiers 
1. Thirty-six-year old male who committed suicide during 
an ‘uncontrollable rage’ three weeks after returning home, 
having served 10 months in Iraq. It is reported that he 
drank excessively and ‘self-medicated’ in the time leading 
up to his suicide. 
2. A military policeman in Baghdad (unknown age), who 
took mefloquine during his operations. He suffered from 
long term nightmares and sleeplessness following his 
return home. It is reported that he had returned home 
‘months’ before his suicide. 
Unclassifiable For both cases, no information is 
provided regarding the dose 
used, how long it had been 
taken for and the timing of the 
event in relation to treatment. 
There is also no past medical 
history given for the individual 
concerned and minimal 
information regarding any co-
medications. 
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McBride 1997 
[17] 
Case report 
in a peer-
reviewed 
journal 
A 6-year-old healthy girl resident in the UK of Nigerian 
descent visited Nigeria on a 4-week holiday. She 
commenced mefloquine 125 mg weekly 1 week before 
travel and was still taking this medication on her return. 35 
days after starting mefloquine she developed blistering of 
her lips and oral mucosa with periorbital and facial 
swelling. She subsequently developed erythema and 
blistering of her face, trunk, limbs, and perineum which 
progressed to exfoliation of 95% of her body surface over 
48 h. Complications over 10 days included pyrexia, 
hypotension, diarrhoea, neutropenia, anaemia, paralytic 
ileus, and klebsiella septicaemia. On day 19 of admission 
she developed cardiac asystole and resuscitation was 
unsuccessful. 
Probable The symptoms occurred in a 
reasonable time sequence to 
when mefloquine prophylaxis 
was taken. Extensive 
investigations revealed no 
alternative cause and the 
patient was not taking any other 
medications and had no past 
medical history. The occurrence 
of SJS/erythema multiforme has 
been documented elsewhere in 
association with mefloquine. No 
information is available 
regarding de-challenge. 
Meier 2004 
[18] 
Retrospective 
cohort study 
Two individuals who received a prescription for mefloquine 
(from a cohort of 16,491) committed suicide during the 
‘follow up period’ of this retrospective cohort study. Both 
were males and had stopped treatment over 90 days 
before the date of the event. 
Unclassifiable This was a retrospective analysis 
of prescription data and the 
individuals were never 
contacted. Therefore, it is not 
possible to confirm whether the 
prescriptions were ever taken 
and if so, the duration of 
treatment. There is also no past 
medical history and no 
information about any co-
medications for either 
participant. 
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Nosten 1994 
[19] 
Randomised 
controlled 
trial 
“One woman in the mefloquine group died of septic shock 
after an emergency caesarean section for obstructed 
labour” 
Unlikely This patient died of 
complications related to labour 
rather than mefloquine use. 
Rodor 1990 
[20] 
Case report 
in a peer-
reviewed 
journal 
Case of 22-year-old woman who took a 250 mg of 
mefloquine for malaria prophylaxis. On day 2 after intake, 
she experienced episodes of crying, emotional detachment, 
and low mood. Her symptoms ameliorated on day 5 and 6.  
One week later (following the next dose) there was a 
relapse of symptoms with ideas of reference, of guilt, of 
death, and feelings of body transformation. Five days later 
she was hospitalized after a suicide attempt by drowning.  
Physical examination and routine blood tests, ECG and EEG 
were normal. She was discharged from hospital three 
weeks later. 
Possible The symptoms occurred in a 
reasonable time sequence to 
starting mefloquine prophylaxis. 
The patient was released from 
hospital after 3 weeks, which is 
the half-life of mefloquine. No 
information is provided 
regarding this patient’s past 
medical history or any other 
medications she had taken or 
was currently taking. 
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Table 2. Reports of death from spontaneous drug reporting databases with insufficient information to apply causality assessment 
Database searched Reference Type of study Dates of search Search criteria Description of included cases 
National French 
Pharmacovigilance 
database 
Angles 2003 
[21] 
Peer-reviewed 
journal article 
1 January 1996 to 
31 December 
2000 
Included all drugs used for 
the treatment or prophylaxis 
of malaria in France apart 
from Doxycycline. 
Excluded foetal effects in 
pregnancy, voluntary 
overdose, insufficient 
available information 
regarding the event, and 
instances in drugs were not 
used for malaria 
- Ventricular fibrillation in a 53-
year-old man with no history of 
previous cardiac problems 
Roche Drug Safety 
Department 
Bem 1992 
[22] 
Peer-reviewed 
journal article 
1985 to May 
1991 
All spontaneously reported 
adverse drug reactions 
- No deaths were reported. 
- 1 suicide attempt in a 45 year 
old female in 1988 who took 
mefloquine for malaria 
prophylaxis for 3 weeks, who 
was hospitalized. She had a 
history of paranoia after taking 
chloroquine and had an 
(unspecified) family history of 
mental health problems. She was 
also taking gringko, gemfibrozil 
and nomogestrol. 
- 1 suicide attempt in a 33 year 
old male in 1989, who took 
mefloquine for malaria 
prophylaxis for 3 weeks. States 
he had no risk factors. 
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- 1 suicide attempt in a 29 year 
old female in 1989, who took 
mefloqine for malaria 
prophylaxis for 2 weeks. States 
she had no risk factors. 
- 1 suicide attempt in a 23 year 
old female in 1990, who took 
mefloquine for malaria 
prophylaxis for 2 weeks. States 
she had no risk factors. 
Nosten 1999 
[23] 
Peer-reviewed 
journal article 
Unclear Not specified - Reports 4 deaths in users of 
mefloquine due to: fatal toxic 
epidermal necrolysis, myocardial 
infarction (following halofantrine 
treatment), pulmonary 
carcinoma and myocarditis 
Schlagenhauf 
2001 [24]
 
 
  
Conference 
proceedings 
1985 to June 
2000 
Serious adverse event 
reports of suicide and/ or 
depression. Exclusion criteria 
included treatment dose, 
overdose, indication and 
dose unknown and 
prescribing errors. 
Reports 8 cases of suicide in 
participants who had used 
mefloquine, all male aged 23-55 
years old. Three cases had pre-
existing psychiatric disorders, 4 
did not and one case was 
unknown. In four cases the 
latency period was 3-47 days. In 
2 cases the suicide occurred 
months or years after 
prophylaxis use. 
WHO 1991 
[25] 
WHO report September 1985 
to July 1991 
Adverse events which 
occurred during clinical trials 
or during routine use of the 
- No deaths were reported 
- 1 suicide attempt in a 33 year 
old male who took mefloquine 
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drug for malaria prophylaxis for 3 
weeks. Reports he had no family 
history of mental health 
problems 
- 1 suicide attempt in a 22 year 
old female who took mefloquine 
for malaria prophylaxis for 2 
weeks. Reports she had no 
family history of mental health 
problems 
Spanish 
Pharmacovigilance 
system 
Aldea 2012 
[26] 
Peer-reviewed 
journal article 
2004 to 2009 Adverse drug reactions in 
individuals aged 0 to 17 years 
- 1 sudden death in a 1 year old 
male in 2006 
- 1 sudden death in a 2 year old 
male in 2006 
UK Medicines and 
Healthcare 
Products 
Regulatory Agency 
Yellow Card 
Scheme 
Smith 1999 
[27] 
 
Peer-reviewed 
journal article 
Up to July 1998 Not specified “A total of 8 fatal reactions” 
Thomas 2014 
[28] 
Peer-reviewed 
journal article 
1964 to 25
th
 
January 2012 
All reports associated with 
the Higher Level Terms 
(HLTs) from the Medical 
Dictionary for Regulatory 
Affairs (MedDRA): (a) 
Depressive disorders; and (b) 
Suicidal and self injurious 
behavior. 
Reports 8 suicides associated 
with mefloquine 
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US Food and Drug 
Administration 
(FDA) 
Anon 2002 
[29] 
Commentary 
in non-profit 
organization 
review article 
October 2000 to 
2001 
Unclear Among 600 reports related to 
mefloquine, “13 who had 
suicidal thoughts, 4 who 
attempted suicide, and 1 who 
committed suicide.” 
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Table 3. Characteristics of excluded studies 
Reference Reason for exclusion 
Anonymous 1990 [37] Refers to a ‘Cardiopulmonary arrest one patient who was taking propranolol (Inderal; and others) after a single 
dose of mefloquine’. No reference is provided and the dose used was not mentioned. 
Anonymous 1996 [38] 
 
Refers to 3 users of mefloquine prophylaxis with ‘suicidal tendencies’, but does not provide sufficient detail to 
meet our definition of para-suicide. 
Anonymous 2000 [39] 
 
Refers to a case report of a suicide in a Dutchman who took mefloquine at a treatment dose. 
Anonymous 2009 [40] 
 
Refers to a case report of death already included within our analysis [12,13]. 
Abecasis 2009 [41] Refers to a death and does not provide a reference. However, the description of the case matches an included 
case report [12,13]. 
Alisky 2006 [42] 
 
Refers to a cohort study already included within our analysis [18]. 
Alikadi 2007 [43] 
 
Refers to case reports of mefloquine being linked to suicide, however, the reference(s) provided do not include 
any reports of death or parasuicide [44]. 
Chattopadhyay 2007 [45] Refers to a case report already included within our analysis [17]. 
Croft 2000 [46] 
 
Refers to a case report(s) of death already included within our analysis [17,27,37], as well as review articles we 
have screened separately. 
Croft 2007 [47] Refers to a review article, which we have analysed separately within the review [46]. 
Croft 2007a [48] Refers to case report(s) of death already included within our analysis [12,13,34,35,37]. 
Croft 2007b [49] 
 
Refers to a case report(s) of death already included within our analysis [12,13,17,34,35], as well as review articles 
we have screened separately. 
Croft 2007c [50] Refers to a review article, which we have analysed separately within the review [49]. 
Croft 2008 [51] 
 
Refers to a case report(s) of death already included within our analysis [17], as well as review articles we have 
screened separately. 
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Croft 2010 [52] 
 
Refers to a review article, which we have analysed separately within the review [8]. 
Croft 2015 [53] 
 
Refers to a death in a user of mefloquine prophylaxis, but the reference provided is a newspaper article. 
Croft 2016 [54] 
 
Mentions that “on or around 20 December 1995, a UK soldier who was taking mefloquine during an Army run 
clinical trial in Kenya killed himself”. However no reference is provided and there is no information about the 
mefloquine dose used. 
Eaton 2009 [55] 
 
Refers to a review article, which we have analysed separately within the review [8]. 
Eber 2003 [56] 
 
Reports that “rare cases of suicide have been reported” [with mefloquine use] but does not provide a reference. 
Embrey 2009 [57] 
 
Reports that “rare cases of suicide and suicidal ideation have been reported” [with mefloquine use] but does not 
provide a reference. 
Fauman 2012 [58] 
 
Refers to an internal policy memorandum within the US military which we have analysed separately [57]. 
Forrester 2016 [59] 
 
Refers to a review article, which we have analysed separately within the review [60]. 
Gogtay 2015 [61] 
 
Refers to “suspected reactions of …depression, sometimes leading to suicide” but does not provide a reference. 
Jousset 2006 [34, 35] 
 
Two different publications were available describing this case. Through personal communication with the author 
we were able to establish that both publications refer to the same case, and that mefloquine was taken at 
treatment dose. 
Hennequin 1994 [62] 
 
Refers to case reports of mefloquine being linked to suicide. However, the reference(s) provided do not include 
any reports of death or para-suicide [63]. 
Jacquieroz 2009 [30] 
 
Refers to a case report(s) of death already included within our analysis [12, 13, 17, 18, 27,  34, 35, 39], as well as 
review articles we have screened separately and newspaper articles. 
Jacquieroz 2015 [9] 
 
Refers to a case report(s) of death already included within our analysis [12, 13, 17, 18, 27,  34, 35, 39], as well as 
review articles we have screened separately and newspaper articles. 
Jha 2006 [64] 
 
Refers to a drug database analysis we have already included in our analysis [27] 
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Jong 2001 [65] 
 
Refers to review articles, which we have analysed separately within the review [66]. 
Kingma 2002 [67] 
 
Reports that “rare cases of suicide and suicidal ideation have been reported” [with mefloquine use] but does not 
provide a reference. 
Kukoyi 2003 [68] 
 
Refers to case reports of mefloquine being linked to suicide. However, the reference(s) provided do not include 
any reports of death or para-suicide [69]. Also includes references to newspaper articles. 
Livesey 2016 [70] 
 
Reports that “neuropsychiatric side effects attributed to mefloquine use [include] suicide” but no reference is 
provided. 
Lopez-Velez 2003 [71] 
 
Refers to review articles, which we have analysed separately within the review [24, 46]. 
Luzzi 1993 [72] 
 
Refers to review articles, which do not include any reports of death [63]. 
Mawson 2013 [73] 
 
Refers to a death in a user of mefloquine prophylaxis, but the reference provided is a newspaper article. 
McCarthy 2005 [74] 
 
Refers to “mefloquine [being] responsible for fatal assaults committed by Canadian soldiers in Somalia and 
British soldiers in Sierra Leone” but does not provide a reference. 
McCarthy 2015 [75] 
 
Refers to a case report of death already included within our analysis [34,35], as well as review articles analysed 
separately. 
McEvoy 2015 [76] 
 
Refers to a case report of death already included within our analysis [34,35]. 
Nevin 2010 [77] 
 
Refers to a death in a user of mefloquine prophylaxis, but the reference provided is a newspaper article. 
Nevin 2012 [78] 
 
Refers to a case report of death already included within our analysis [34,35]. 
Nevin 2012a [79] 
 
A case report which includes a description of an “impulsive act” “designed to feel fear”, which does not meet our 
definition of para-suicidal. 
Nevin 2012b [80] 
 
Refers to a case report of death already included within our analysis [34,35], as well as a review article we have 
analysed separately [49] 
Nevin 2015 [81] 
 
Refers to review articles, which we have analysed separately within the review [60,82] as well as newspaper 
articles 
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Nevin 2015a [82] 
 
Refers to case report(s) of death already included within our analysis [34,35] as well as review articles we have 
analysed separately [49]. 
Nevin 2016 [83] 
 
Refers to case report(s) of death already included within our analysis [34,35,39]. 
Nevin 2017 [84] 
 
This paper performed a drug safety database analysis of the US Food and Drug Administration Adverse Event 
Reporting System. However, they did not report individual cases, and instead reported on “suicidal and self 
injurious behaviour" which does not meet our inclusion criteria. 
Ritchie 2013 [60] 
 
Refers to a case report(s) of death already included within our analysis [17,34,35], as well as review articles we 
have screened separately and newspaper articles. 
Schlagenhauf 1999 [66] 
 
Refers to case report(s) of death already included within our analysis [17]. 
Tango 2003 [85] 
 
Refers to case reports of mefloquine being linked to suicide. However, the reference(s) provided do not include 
any reports of death or para-suicide [86], as well as a review articles we have analysed separately. 
WHO 2001 [87] 
 
Refers to a review article, which we have analysed separately within the review [23]. 
Willmore 2006 [88] 
 
Refers to a drug safety database analysis which we have analysed separately within the review [25]. 
Wittes 1995 [69] 
 
Refers to a review article, which we have analysed separately within the review [22]. 
Wooltorton 2002 [89] 
 
Refers to case reports of mefloquine being linked to suicide, however, the reference(s) provided do not include 
any reports of death or para-suicide [44,69] 
